Table 2.
Univariate Cox proportional hazard analysis for progression-free survival in patients with IDH-mutant WHO grade 2 and grade 3 astrocytoma. Univariate analysis of the entire study cohort was performed using log-rank tests to assess the association of clinical and histopathological parameters with progression-free survival. Results are presented as hazard ratios with 95% confidence intervals. P values are given, asterisks indicate p ≤ 0.05
| Univariate analysis for WHO grade 2 and 3 astrocytoma | ||||
|---|---|---|---|---|
| Variable | Type of variable | Progression Free Survival | ||
| Hazard ratio | 95% confidence interval | p-value | ||
| WHO Grade | Grade 3 (versus grade 2) | 1,50 | 0.87–2,52 | 0.13 |
| Surgery | biopsy (versus resection) | 1.17 | 0.46–3.32 | 0.76 |
| Histologic features | ||||
| Mitotic count | continuous | 1.37 | 1.02–1.81 | *0.03 |
| Ki67 proliferation index | continuous | 1.04 | 1.00–1.08 | *0.03 |
| Demographics | ||||
| Sex | male (versus female) | 0.68 | 0.41–1.13 | 0.14 |
| Age (years) | continuous (older) | 0.98 | 0.95–1.00 | 0.07 |
| Clinical and Radiological markers | ||||
| Contrast enhancement | enhancing (versus non-enhancing) | 2.05 | 1.17–3.58 | *0.01 |
| KPS at diagnosis | continuous (higher) | 1.04 | 0.53–1.94 | 0.9 |
| Molecular markers | ||||
| MGMT promotor status | unmethylated (versus methylated) | 1.05 | 0.24–4.91 | 0.57 |
| TERT | mutated (versus non-mutated) | 1.30 | 0.07–6.34 | 0.8 |